Novel MDM2 Inhibitor XR-2 Exerts Potent Anti-Tumor Efficacy and Overcomes Enzalutamide Resistance in Prostate Cancer

Background: The inactivation of tumor-suppressor p53 plays an important role in second generation anti-androgens (SGAs) drug resistance and neuroendocrine differentiation in castration-resistant prostate cancer (CRPC). The reactivation of p53 by blocking the MDM2–p53 interaction represents an attrac...

Descripción completa

Detalles Bibliográficos
Autores principales: Wu, Meng, Cui, Jingyi, Hou, Huimin, Li, Ying, Liu, Shengjie, Wan, Li, Zhang, Lili, Huang, Wei, Sun, Gaoyuan, Liu, Jingchao, Jin, Pengfei, He, Shunmin, Liu, Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9081362/
https://www.ncbi.nlm.nih.gov/pubmed/35548335
http://dx.doi.org/10.3389/fphar.2022.871259

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9081362/
https://www.ncbi.nlm.nih.gov/pubmed/35548335
http://dx.doi.org/10.3389/fphar.2022.871259

Ejemplares similares